AIGEN Sciences Inc. is revolutionizing drug discovery with its award-winning AI platform. Their unique approach directly identifies high-potency drugs, minimizing off-target effects and toxicity. They aim to transform high-cost, low-efficiency drug discovery practices into rapid, efficient solutions that lead to high success rates in clinical phases.

Vision and Mission: AIGEN’s vision is to advance current state-of-the-art AI drug discovery technologies, ultimately improving patient health and saving lives. Their mission is to create a regenerative future by providing accessible, sustainable, and innovative solutions for drug development.

Noteworthy Points:

• AIGEN Sciences was established in April 2021 as a spin-off of Korea University’s DMIS Lab.
• They collaborate with industry leaders, including YUHAN, NOVELTY NOBILITY Inc., and Avelos Therapeutics, focusing on anti-cancer drugs, ADC payload development, and autoimmune diseases.
• AIGEN’s proprietary quantized AI runs exclusively on renewable energy, making it a pioneer in sustainable drug discovery.